Photo from wikipedia
Despite terizidone being part of the second‐line recommended drugs for treatment of drug‐resistant tuberculosis (DR‐TB), information on its pharmacokinetics is scarce. The aim of this study was to describe the… Click to show full abstract
Despite terizidone being part of the second‐line recommended drugs for treatment of drug‐resistant tuberculosis (DR‐TB), information on its pharmacokinetics is scarce. The aim of this study was to describe the steady‐state population pharmacokinetics (PPK) of terizidone and its primary metabolite cycloserine in patients with DR‐TB and determine the effect of patient characteristics.
Keywords:
metabolite cycloserine;
state population;
drug resistant;
population pharmacokinetics;
steady state;
resistant tuberculosis
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!